COMP <GO>
CRSP vs JNJ // EV/EBITDA & P/E VALUATION
CRISPR Therapeutics AG (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CRSP 2
— JNJ 9
■ METRIC PARITY
LAST: $54.26 (+0.28%) • MKT CAP: $5.25B
valuation
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | 25.50% | -56.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | 2.97% | -9.56 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 6.00% | -71.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 5.59 | +2.38 | CRSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 62.1 | -7.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.08 | +0.04 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 23.0x | +5.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.25B | $662.49B | -$657.25B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | JNJ REV | CRSP GROSS % | JNJ GROSS % | CRSP FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $94.19B | — | 67.9% | -$345.9M | $19.70B |
| FY 2024 | $37.3M | $88.82B | — | 69.1% | -$144.7M | $19.84B |
| FY 2023 | $371.2M | $85.16B | — | — | -$277.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
JNJ // BETA 1.08